1887
Volume 2021, Issue 3
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

The coronavirus disease 2019 (COVID-19) has affected almost every country worldwide, including all 22 Arab countries. To the best of our knowledge, this is the first study to follow the prevalence of COVID-19 in all Arab countries. In this review, we aimed to assess the 12-month prevalence of COVID-19 in Arab countries and to compare these findings with other significantly affected countries. World Health Organization, Worldometer, and Ministries of Health websites were used to search for COVID-19 data in all Arab countries. The period covered started from February 2020 to February 2021. In all Arab countries, the median age of the population was 26.25 years. As of March 01, 2021, the total number of confirmed COVID-19 cases in all Arab countries was 4,259,756. Bahrain, Qatar, Lebanon, Kuwait, and United Arab Emirates had the highest reported number of confirmed COVID-19 cases per million population. The total number of COVID-19 deaths was 72,950, with predominance in Lebanon, followed by Tunisia, Jordan, Palestine, and Iraq. In comparison with the topmost affected countries, and based on both the highest number of confirmed and deaths per million population, Arab countries ranked second last before India, with 9,646 and 165 cases, respectively. Among the Arab countries, Qatar, Bahrain, and Lebanon showed the highest number of recovered, confirmed, and death cases per million populations, respectively. The number of confirmed and death cases among all Arab countries triggered significant worries about morbidity and mortality of COVID-19, respectively. However, the younger population in Arab countries may have contributed to fewer COVID-19 deaths in comparison with the topmost affected countries.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2021.66
2021-11-25
2022-05-27
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2021/3/qmj.2021.66.html?itemId=/content/journals/10.5339/qmj.2021.66&mimeType=html&fmt=ahah

References

  1. World Population Clock - Worldometer (2020). [Internet]. Available from: https://www.worldometers.info/world-population. Accessed online 16 August 2021.
  2. Paraskevis D, Kostaki EG, Magiorkinis G, Panayiotakopoulos G, Sourvinos G, Tsiodras S. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect Genet Evol 2020; 79:: 104212.
    [Google Scholar]
  3. Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020; 9:: 221–36.
    [Google Scholar]
  4. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol2020; 5(4): 536–44.
    [Google Scholar]
  5. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382:: 727–33.
    [Google Scholar]
  6. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J. et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med 2020; 382:: 1708–20.
    [Google Scholar]
  7. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 2020; 382:: 970–1.
    [Google Scholar]
  8. Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016; 14:: 523–34.
    [Google Scholar]
  9. Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Emerg Microbes Infect 2020; 76:: 71–6.
    [Google Scholar]
  10. Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020; 75:: 1730–41.
    [Google Scholar]
  11. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020; 94:: 91–5.
    [Google Scholar]
  12. Lu X, Zhang L, Du H, Zhang J, Li Y, Qu J, et al. SARS-CoV-2 infection in children. N Engl J Med 2020; 382:: 1663–5.
    [Google Scholar]
  13. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis 2020; 20:: 689–96.
    [Google Scholar]
  14. Wenham C, Smith J, Morgan R. COVID-19: the gendered impacts of the outbreak. Lancet 2020; 395:: 846–8.
    [Google Scholar]
  15. Jin JM, Bai P, He W, Wu F, Liu X, Han D, et al. Gender differences in patients with COVID-19: Focus on severity and mortality. Front Public Health 2020; 8:: 152.
    [Google Scholar]
  16. Hall KS, Samari G, Garbers S, Casey SE, Dixon Diallo D, Orcutt M, et al. Centring sexual and reproductive health and justice in the global COVID-19 response. Lancet 2020; 395:: 1175–7.
    [Google Scholar]
  17. Lin C, Tu P, Beitsch LM. Confidence and receptivity for COVID-19 vaccines: A rapid systematic review. Vaccines (Basel) 2020; 9:: 16.
    [Google Scholar]
  18. Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med 2021; 27:: 225–8.
    [Google Scholar]
  19. Bagcchi S. The world's largest COVID-19 vaccination campaign. Lancet Infect Dis 2021; 21:(3): 323.
    [Google Scholar]
  20. Toffolo, Chris. Global Organizations: The Arab League. New York: Chelsea House, 2008. Introduction to the League of Arab States, p: 7–24.
  21. Alwahaibi N, Al-Maskari M, Al-Dhahli B, Al-Issaei H, Al-Bahlani S. A review of the prevalence of COVID-19 in the Arab world. J Infect Dev Ctries 2020; 14:: 1238–45.
    [Google Scholar]
  22. Alshahrani NZ, Alshahrani SM, Alshahrani AM, Leggat PA, Rashid H. Compliance of the Gulf cooperation council airlines with COVID-19 mitigation measures. J Travel Med 2021; 28:(2): 205.
    [Google Scholar]
  23. Alandijany T, Faizo A, Azhar E. Coronavirus disease of 2019 (COVID-19) in the Gulf Cooperation Council GCC countries: Current status and management practices. J Infect Public Health 2020; 13:: 839–42.
    [Google Scholar]
  24. Li Y, Jia W, Wang J, Guo J, Liu Q, Li X, et al. Alert-COVID: Attentive lockdown-aware transfer learning for predicting COVID-19 pandemics in different countries. J Healthc Inform Res 2021; 5:: 98–113.
    [Google Scholar]
  25. Alyami M, Naser A, Orabi M, Alwafi H, Alyami H. Epidemiology of COVID-19 in the Kingdom of Saudi Arabia: An ecological study. Front Public Health 2020; 8:: 506.
    [Google Scholar]
  26. Adly H, AlJahali I, Garout M, Khafagy A, Saati A, Saleh S. Correlation of COVID-19 pandemic with healthcare system response and prevention measures in Saudi Arabia. Int J Environ Res Public Health 2020; 17:: 1–13.
    [Google Scholar]
  27. Saudi Arabia extends covid measures by another 20 days. News Article by Argus published on 14. Feb. 2021. [Internet]. Available from: https://www.argusmedia.com/en/news/2186868-saudi-arabia-extends-covid-measures-by-another-20-days. Accessed online 14 February 2021.
  28. Malkey M, Al-Sammak M. Incidence of COVID-19 in Iraq-implications for travelers. Travel Med Infect Dis 2020; 38:: 1–3.
    [Google Scholar]
  29. Sarhan A, Flaih M, Hussein T, Hussein K. Novel coronavirus (COVID-19) outbreak in Iraq. The first wave and future scenario. MedRxiv preprint 2020. doi: https://doi.org/10.1101/2020.06.23.20138370 .
    [Google Scholar]
  30. Latest on the region's Covid-19 recovery. [Internet]. Middle East Business Intelligence. Available from: https://www.meed.com/latest-news-on-the-pandemics-economic-impact. Accessed online 14 February 2021.
  31. Paladugu S, Donato A. Remdesivir improved time to recovery in adults hospitalized with COVID-19 and lower respiratory tract involvement. Ann Intern Med 2020; 173:: JC4.
    [Google Scholar]
  32. Malgie J, Schoones J, Pijls B. Decreased mortality in coronavirus disease 2019 patients treated with tocilizumab: a rapid systematic review and meta-analysis of observational studies. Clin Infect Dis 2020; 2:: 1–8.
    [Google Scholar]
  33. Hasan M, Rabbani R, Anam A, Huq S. Additional baricitinib loading dose improves clinical outcome in COVID-19. Open Medicine 2020; 16:: 041–6.
    [Google Scholar]
  34. Horwitz L, Jones S, Cerfolio R, Francois F, Greco J, Rudy B, et al. Trends in COVID-19 risk-adjusted mortality rates. J Hosp Med 2020; 16:: 90–2.
    [Google Scholar]
  35. Monye I, Adelowo AB. Strengthening immunity through healthy lifestyle practices: Recommendations for lifestyle interventions in the management of COVID-19. Lifestyle Med 2020; 1:: e7.
    [Google Scholar]
  36. Boehmer TK, DeVies J, Caruso E, van Santen KL, Tang S, Black CL, et al. Changing age distribution of the COVID-19 pandemic–United States, May–August 2020. MMWR Morb Mortal Wkly Rep 2020; 69:: 1404–9.
    [Google Scholar]
  37. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 2020; 20:: 669–77.
    [Google Scholar]
  38. Alinier G, Morris B, Abu J, Al Shaikh L, Owen R. Implementation of a drive-through testing clinic in Qatar for residents having recently returned from a country with a COVID-19 travel warning. Qatar Med J 2021; 2020:(3): 3:(2021): 42.
    [Google Scholar]
  39. Esteve A, Permanyer I, Boertien D, Vaupel JW. National age and coresidence patterns shape COVID-19 vulnerability. Proc Natl Acad Sci U S A 2020; 117:: 16118–20.
    [Google Scholar]
  40. Lau H, Khosrawipour T, Kocbach P, Ichii H, Bania J, Khosrawipour V. Evaluating the massive underreporting and undertesting of COVID-19 cases in multiple global epicenters. Pulmonology 2021; 27:(2): 110–5.
    [Google Scholar]
  41. Oksanen A, Kaakinen M, Latikka R, Savolainen I, Savela N, Koivula A. Regulation and trust: 3-month follow-up study on COVID-19 mortality in 25 European countries. JMIR Public Health Surveill 2020; 6:: e19218.
    [Google Scholar]
  42. Wu J, Leung TK, Bushman M, Kishore N, Niehus R, de Salazar PM, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med 2020; 26:: 506–10.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2021.66
Loading
/content/journals/10.5339/qmj.2021.66
Loading

Data & Media loading...

  • Article Type: Review Article
Keyword(s): Arab worldcoronavirusCOVID-19 and SARS-CoV-2
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error